It's time to propose a uniform criteria for determining 'clinical complete response' in hepatocellular carcinoma

分享到

Link by DOI

作者单位: Affiliations ¹ Department of HPB Surgery, Shandong Cancer Hospital Affiliated to Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China. ² Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ³ Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China.

摘要: Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form . HZ serves as an unpaid Deputy Editor-in-Chief of Hepatobiliary Surgery and Nutrition. LZ reports support from the Key Research and Development Program of Shandong , 2021SFGC0501, and is on the speakers’ bureau for Bayer, MSD, Roche, BiGene, Innovent, Hengrui Medicine. HZ had received speaker fees from AstraZeneca, Bayer, BeiGene, Eisai, Hengrui, Innovent, MSD, and Roche. HS had received spe...更多; Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form . HZ serves as an unpaid Deputy Editor-in-Chief of Hepatobiliary Surgery and Nutrition. LZ reports support from the Key Research and Development Program of Shandong , 2021SFGC0501, and is on the speakers’ bureau for Bayer, MSD, Roche, BiGene, Innovent, Hengrui Medicine. HZ had received speaker fees from AstraZeneca, Bayer, BeiGene, Eisai, Hengrui, Innovent, MSD, and Roche. HS had received speaker fees from AstraZeneca, Bayer, BeiGene, Eisai, Hengrui, Innovent, MSD, Roche, TopAlliance, and Zelgen. The authors have no other conflicts of interest to declare.收起

列表公用js 卡片页统计